Open Access

REVIEW

Caroline Jamison^*, Debra Nelson^†, Mete Eren^†, Dron Gauchan^†, Ryan Ramaekers^†, Max Norvell^†, Mehmet Sitki Copur^†
Oncology Research, Vol.23, No.1-2, pp. 1-5, 2015, DOI:10.3727/096504015X14452563485986
Abstract Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg once daily after demonstration of the same efficacy with less toxicity. Some patients require significant dose reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients may require further dose reductions due to substantial toxicity while maintaining good control of their disease. We report two CP-CML patients achieving and maintaining major molecular responses More >

View

146

Download

88

Open Access

ARTICLE

Fei Meng, Wei Liu
Oncology Research, Vol.23, No.1-2, pp. 7-12, 2015, DOI:10.3727/096504015X14410238486649
Abstract Cervical cancer is the second leading type of cancer in women living in less developed countries. The pathological and molecular mechanisms of cervical cancer are not comprehensively known. Though legumain has been found to be highly expressed in various types of solid tumors, its expression and biological function in cervical cancer remain unknown. In this study, we aimed to investigate legumain expression and functions in cervical cancer. We found that legumain was highly expressed in cervical cancer cells. When knocked down, legumain expression in HeLa and SiHa cells significantly reduced its migration and invasion abilities More >

View

158

Download

96

Open Access

ARTICLE

Yun Qin^*, Xicai Tang^†, Mingxing Liu^‡
Oncology Research, Vol.23, No.1-2, pp. 13-20, 2015, DOI:10.3727/096504015X14410238486766
Abstract The purpose of this study was to assess the effects of NBPF1 expression on cervical cancer cell invasion and apoptosis and to illustrate its potential mechanism. Human cervical cancer HeLa cells were transfected with the constructed siNBPF1 or pcDNA3.1-NBPF1 vectors. Effects of NBPF1 expression on cell invasion ability and cell apoptosis were analyzed using the Matrigel method and an Annexin V-FITC cell apoptosis kit, respectively. In addition, cell apoptosis-related proteins involved with the PI3K/mTOR signaling pathway were analyzed using Western blot. Remediation experiments were conducted to verify the effects of NBPF1 expression on cell invasion… More >

View

167

Download

158

Open Access

ARTICLE

Wunchana Seubwai^*†‡, Kulthida Vaeteewoottacharn^‡§, Ratthaphol Kraiklang^¶, Kazuo Umezawa^#, Seiji Okada^**, Sopit Wongkham^‡§
Oncology Research, Vol.23, No.1-2, pp. 21-28, 2015, DOI:10.3727/096504015X14424348426071
Abstract Cholangiocarcinoma (CCA) is a dismal cancer. At present, there is no effective chemotherapeutic regimen for CCA. This may be due to the marked resistance of CCA to chemotherapy drugs, for which a mechanism remains unknown. Nuclear factor-kB (NF-kB) is constitutively activated in a variety of cancer cells, including CCA. It has been shown to play roles in growth, metastasis, and chemoresistance of cancer. In the present study, we examined whether NF-kB is involved in the chemoresistance of CCA and whether dehydroxymethylepoxyquinomicin (DHMEQ), an effective NF-kB inhibitor, can overcome the drug resistance of CCA. Two CCA… More >

View

190

Download

94

Open Access

ARTICLE

Xiang Zhou^*1, Weiming Wang^†1, Pihong Li^*, Zhiqiang Zheng^*, Yangyang Tu^*, Yi Zhang^*, Tao You^*
Oncology Research, Vol.23, No.1-2, pp. 29-34, 2015, DOI:10.3727/096504015X14452563486011
Abstract Despite the efficacy of fluoropyrimidines and oxaliplatin-based chemotherapy for patients, this treatment leads to significant patient inconvenience, toxicity, and cost. This study aims to validate a nontoxic agent, curcumin, to the current chemotherapeutic regimen. In in vitro experiments, curcumin induced apoptosis in gastric cancer cell line BGC-823. Synergistic antitumor effects of curcumin were observed in combination with 5-fluorouracil (5-FU) and oxaliplatin. These effects were accompanied by downregulation of the expression of Bcl-2 protein and mRNA and upregulation of the expression of Bax and caspase 3, 8, and 9. In addition, the in vivo study showed More >

View

178

Download

89

Open Access

ARTICLE

Zhi-jian Meng^*, Ke Tao^†
Oncology Research, Vol.23, No.1-2, pp. 35-41, 2015, DOI:10.3727/096504015X14452563486057
Abstract Reports show that the stathmin gene may have a close relationship with tumor chemotherapeutic sensitivity. However, the effect of stathmin-1 on the chemosensitivity of gastric cancer to docetaxel has not been clearly determined. siRNA targeting stathmin-1 was introduced. The cell growth inhibition, expression of associated proteins, cell cycle, and apoptosis were evaluated by MTT, Western blot, and flow cytometric assays, respectively. The influence of silencing stathmin-1 was detected in situ and in vivo. SGC7901/docetaxel cells are the drug-resistant cells. After silencing stathmin-1, the resistance index (RI) reduced to 3.41, the expressions of STMN-1, MDR1, and More >

View

133

Download

111

Open Access

ARTICLE

Anqi Yin^*†1, Chengguo Wang^‡1, Jiachen Sun^*1, Jianjun Gao^§, Liang Tao^†, Xilin Du^‡, Huadong Zhao^‡, Jiandong Yang^§, Yan Li^*†
Oncology Research, Vol.23, No.1-2, pp. 43-51, 2015, DOI:10.3727/096504015X14452563486093
Abstract Medullary thyroid carcinoma (MTC) is an uncommon and highly aggressive tumor of the neuroendocrine system, which derives from the neuroendocrine C cells of the thyroid gland. Except for surgical resection, there are not very many effective systemic treatment options for MTC. N-Myc downstream-regulated gene 2 (NDRG2) had a significantly lower expression in MTC compared with normal thyroid tissue. However, the function of NDRG2 in MTC oncogenesis is largely unknown. In this study, we found that overexpression of NDRG2 inhibited the proliferation of TT cells (human medullary thyroid carcinoma cells) in vitro and suppressed the development of MTC… More >

View

140

Download

88

Open Access

ARTICLE

Feng Xi^*, Jianghao Ye^†
Oncology Research, Vol.23, No.1-2, pp. 53-59, 2015, DOI:10.3727/096504015X14459480491740
Abstract Hexokinase 2 (HK2) has been identified as an oncogene in some malignant diseases such as breast cancer and ovarian cancer. However, the role of HK2 in lung cancer remains unclear. In this study, we explored the functional role of HK2 in lung cancer cell proliferation and tumorigenesis and determine its expression profile in lung cancer. HK2 expression was increased in primary lung cancer tissues of patients. Knocking down HK2 expression by small interfering RNA (siRNA) inhibited cell proliferation in lung cancer cells and nude mice. Thus, HK2 is required for sustained proliferation and survival of More >

View

163

Download

81

Open Access

ARTICLE

Yan Zhen^*1, Dongming Li^*†1, Wen Li^*, Weimin Yao^*†1, Aibing Wu^‡, Jing Huang^‡, Hongli Gu^*†, Yujie Huang^*†, Yajun Wang^*, Jun Wu^*†, Min Chen^*†, Dong Wu^*†, Quanchao Lyu^*, Weiyi Fang^§, Bin Wu^*†
Oncology Research, Vol.23, No.1-2, pp. 61-68, 2015, DOI:10.3727/096504015X14478843952861
Abstract It is largely recognized that PDCD4 is frequently lost in tumors of various origins, including lung cancer, and its loss contributes to tumor progression. However, its role and molecular mechanism remain largely unexplored in non-small cell lung cancer (NSCLC). In this study, downregulated PDCD4 mRNA expression was found in NSCLC tissues compared to their corresponding paracarcinoma tissues and distal paracarcinoma tissues. Induced expression of PDCD4 inhibited cell growth and proliferation and cell cycle transition in vitro. Conversely, knocking down PDCD4 expression promoted cell growth and proliferation. Mechanistically, PDCD4 inactivated PI3K/Akt signaling and its downstream cell More >

View

187

Download

87

Open Access

ARTICLE

Encieh Choghaei^*, Gholamreza Khamisipour^†, Mojtaba Falahati^*, Behrooz Naeimi^†, Majid Mossahebi-Mohammadi^‡, Rahim Tahmasebi^†, Mojtaba Hasanpour^†, Shakib Shamsian^†, Zahra Sadat Hashemi^§
Oncology Research, Vol.23, No.1-2, pp. 69-78, 2015, DOI:10.3727/096504015X14478843952906
Abstract Breast cancer is the most commonly occurring cancer among women. MicroRNAs as noncoding small RNA molecules play pivotal roles in cancer-related biological processes. Increased levels of microRNA-29a in the serum of breast cancer patients have been reported. Since heat shock proteins (HSPs) play important roles in cell events, the quantitative fluctuations in their cellular levels could be deemed as key indicators of how the exerted treatment alters cell behavior. In this regard, using an antisense small RNA, we attempted to investigate the effects of miR-29a knockdown on the expression of HSPs genes in the MCF-7… More >

View

162

Download

79

Open Access

ARTICLE

Jian-lin Yang^*1, Ye Qin^*1, Liang Li^†, Chu-yu Cao^*, Qing Wang^*, Qian Li^*, Ya-feng Lv^*, Yanlin Wang^*
Oncology Research, Vol.23, No.1-2, pp. 79-86, 2015, DOI:10.3727/096504015X14478843952942
Abstract In the process of tumor cell apoptosis induced by specific regents, calreticulin (CRT) was transferred from endoplasmic reticulum (ER) onto the cell membrane. These tumor cells, when used as the cellular vaccine to immunize experimental animals, could initiate effective antitumor immunoresponse against homologous tumor cells. This is referred to as immunogenic cell death. Lidamycin (LDM) is an enediyne antibiotic, which has extremely potent cytotoxicity to cancer cells. In this study, the mouse melanoma B16-F1 cancer cells were used to investigate the ability of LDM in promoting immunogenic cell death. Our data showed that LDM could… More >

View

167

Download

86

Open Access

CORRECTION

Akinobu Furutani^*†, Yoshihiro Sowa^*, Hitoshi Fujiwara^†, Eigo Otsuji^†, Toshiyuki Sakai^*
Oncology Research, Vol.23, No.1-2, pp. 87-87, 2015, DOI:10.3727/096504016X14514194509664
Abstract Histone deacetylase (HDAC) inhibitors have been shown to enhance the effects of 5-fluorouracil (5-FU) against various cancer cells; however, no report has shown that an HDAC inhibitor may enhance the effects of 5-FU with radiation. Therefore, we investigated whether the novel HDAC inhibitor OBP-801/YM753 could enhance the effects of 5-FU with radiation on esophageal squamous carcinoma KYSE170 cells. The inhibition of the cell growth was significantly stronger with the combination of OBP-801/YM753 with 5-FU than with the 5-FU treatment only. Furthermore, inhibition of the colony formation was the most effective with the combined treatment of More >

View

154

Download

93